Which of the following findings would support the diagnosis of statin-induced myopathy?

The choice of high creatine kinase (CK) levels is a key finding that supports the diagnosis of statin-induced myopathy. Statin medications can lead to muscle-related side effects, among which muscle pain and weakness are common. One of the physiological responses to muscle damage is an increase in creatine kinase levels, as this enzyme is released into the bloodstream when muscle tissue is compromised.

Elevated CK levels are indicative of muscle injury and, in the context of a patient who is on statin therapy, can help confirm that the muscle symptoms the patient is experiencing are indeed related to the medication rather than another underlying condition.

The other options are less directly relevant to confirming statin-induced myopathy. For example, elevated liver enzymes can occur due to other reasons unrelated to muscle injury, such as hepatic steatosis or other liver pathologies. Normal immunological tests might suggest that an autoimmune process is less likely but do not specifically indicate myopathy caused by statin use. Low hemoglobin levels could indicate anemia but do not provide information directly relevant to muscle injury or the effects of statins. Therefore, the presence of a high creatine kinase level is the most definitive marker in this scenario to support the diagnosis of statin-induced myopathy.